Re-evaluating pharmaceutical stability in space: A biomedical and regulatory science framework for long-duration...

Area of Science:

• Space Medicine
• Pharmaceutical Science
• Regulatory Science

Background:

• Pharmaceutical stability is crucial for astronaut health and mission success in space.
• Current drug stability regulations (e.g., ICH guidelines) are based on terrestrial conditions and do not account for spaceflight stressors.
• Spaceflight introduces unique environmental challenges like microgravity, radiation, and vacuum exposure.

Purpose of the Study:

• To evaluate the limitations of current pharmaceutical regulatory frameworks for spaceflight.
• To analyze experimental evidence and agency reports on drug degradation in space.
• To propose an improved regulatory science framework for space pharmaceuticals.

Main Methods:

• Systematic review of experimental data, space agency reports, and regulatory documents.
• Analysis of pharmaceutical degradation deviations from Earth-based predictions.
• Identification of regulatory and operational fragmentation issues.

Main Results:

• Pharmaceutical degradation in space is complex, multi-factorial, and formulation-dependent, differing from terrestrial predictions.
• Existing regulatory systems are inadequate for the unique conditions of spaceflight.
• Inconsistent pharmaceutical handling across missions due to fragmented regulatory bodies.

Conclusions:

• A new biomedical and health-centric regulatory science framework is needed for space pharmaceuticals.
• This framework should include environment-specific testing, standardized packaging, and dynamic shelf-life management.
• The proposed framework aims to enhance predictive reliability, mitigate risks, and support astronaut health in deep space missions.